2024/07/16 M Ventures Participates in Asceneuron's $ 100M Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases Funds will be used to progress lead asset into Phase 2 clinical development for the treatment of Alzheimer’s disease
2024/06/29 Metalenz wins AI Breakthrough Award for Best Overall Biometrics Solution Metalenz' Polar ID represents a paradigm shift in how machine vision systems perceive and respond to visual inputs in the rapidly evolving landscape where AI and machine learning drive innovation.
2024/07/16 M Ventures Participates in Asceneuron's $ 100M Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases
2024/06/20 iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
2024/05/21 LabGenius raises £35 million led by M Ventures to further develop its ML-driven antibody discovery platform and progress a pipeline of assets towards the clinic
2024/04/11 Merck KGaA, Darmstadt, Germany’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
2024/04/04 Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology
2024/03/06 Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
2024/01/16 DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
2024/01/08 M Ventures portfolio company Calypso, a Merck KGaA, Darmstadt, Germany spin-out, enters into agreement to be acquired by Novartis